Introduction
Achievements such as the Human Genome Project provide sound foundations for the development of 'individualised medicine'. Therapy tailored to individual genotype may enable prediction of efficacy and adverse events. 1 The Food and Drugs Administration clearly anticipates such developments and encourages the inclusion of pharmacogenomic data for new drugs 2 such as voriconazole, one of the first to include these data. Hence, it is timely to review current knowledge of pharmacogenomics of antifungal drugs and consider whether we might soon individually tailor therapy based on our understanding of genotypic variability in patients.
Absorption, distribution and metabolism of drugs Table 1 presents an overview of factors affecting drug absorption, distribution and metabolism.
Gastric pH varies markedly within the population, with up to tenfold interindividual variation. 3 The impact of gastric pH on absorption of antifungal drugs is most clinically relevant for itraconazole and posaconazole.
Several antifungals are extensively protein bound, rendering them susceptible to variations in the levels of serum proteins, particularly albumin. Recipients of haemopoietic SCT (HSCT) are prone to malnutrition, 4 with consequent reduction in serum proteins. At least in the case of itraconazole, this results in increased levels of unbound drug. 5 Structural variation in plasma proteins, such as is seen in the genetic variants of albumin, 6 ,7 may affect substrate binding, 8 but no relevant data are yet available as to whether this affects antifungal drugs.
Most cellular uptake of drugs occurs by passive diffusion, but some drugs are actively imported, requiring specific transporters (see Table 2 ) and energy expenditure. Most of the transporters exhibit genetic variants, the relative frequency of which varies with ethnicity. [9] [10] [11] This may be reflected in differing transport characteristics and drug levels among ethnic groups. 11 This is relevant to antifungal therapy as several antifungals are substrates or inhibitors of these transporters. The effect of genetic variability of transporters on the cyclodextrin carrier used to solubilise some antifungal drugs is currently unknown.
The cytochrome P450 (CYP450) enzyme system carries out phase I oxidative metabolism of a vast range of endogenous and exogenous substrates, including 75% of all drugs. 12 Drugs metabolised by the same CYP enzymes often interact, 13, 14 and several websites detail the role of CYP enzymes in drug interactions (for example, http:// bioinformatics.charite.de/supercyp/index.php?site ¼ home, http://medicine.iupui.edu/clinpharm/ddis/ and http://www. drugbank.ca/). CYP expression varies with site and age (see Table 1 ) and, in addition, there may be up to 20-fold variability in CYP3A4 activity between individuals. 15 Thus, the same drug given orally to two patients may be subject to different levels of first-pass metabolism and hence achieve very different levels in the circulation. A further complication is the overlapping substrate specificities of CYP3A4 and permeability glycoprotein (P-gp). 16 Interindividual variability of CYP450 enzyme activity is influenced by the frequent presence of allelic singlenucleotide polymorphisms (SNPs), some of which result in reduction or ablation of their metabolic activity. CYP2C19 has over 20 polymorphisms that result in truncated or inactive enzyme 17 and one that causes enhanced activity. 18 Other polymorphic cytochromes involved in antifungal drug metabolism include CYP2C9 19, 20 and CYP3A4/5. 21, 22 The prevalence of these polymorphisms varies in different populations and hence the likelihood of expressing a particular genotype/phenotype varies with ethnicity. In Caucasians, B80% will have wild-type 2C9 alleles and B20% the Intestinal CYPs: 3A (80%), 2C9 (B14%) 132 Liver CYPs: 3A4/5 (29%), 2C (18%), 1A2 (13%) 133 Highest levels of 3A in duodenum and middle jejunum, declining in the distal jejunum and ileum 134 Voriconazole and itraconazole have extensive interactions via the CYP system Relative distribution of each transporter varies in intestines, kidney, liver and brain Genetic variants have been described for almost all the transporters listed here (references describing genetic variants are in bold). As several antifungals interact with these transporters in vitro, potentially they may interact in vivo. commonly occurring variants, resulting in alterations in their substrate affinity. 23 For 2C19, the incidence of the 'poor metaboliser' phenotype associated with inactive 2C19 protein production is 2-6% in Caucasians, but 15-20% in Asians. 17 Phase II metabolic processes, or conjugation reactions, are catalysed by a range of enzymes, including glutathione S-transferase, N-acetyltransferase and uridine 5 0 -diphosphoglucuronosyltransferase (UGT). These enzymes are genetically polymorphic, [24] [25] [26] with some of the resultant enzymes having decreased activity. 26, 27 The CYP enzymes are central to the metabolism of azole antifungals, but some of the phase II enzymes have also been shown to be important for certain antifungal drugs.
Absorption, distribution, metabolism and elimination of antifungal drugs Polyenes Amphotericin B deoxycholate and the lipid formulations of amphotericin B. Amphotericin B deoxycholate is a polyene antifungal first licensed in the late 1950s, but now little used in its original formulation because of its toxicity. It binds to ergosterol in the fungal cell membrane, resulting in pore formation and leakage of cell constituents. 28 The therapeutic advantages provided by the broad spectrum of activity, including yeasts and moulds, are offset by infusion-related toxicity and nephrotoxicity. In contrast, lipid formulations of amphotericin B maintain similar efficacy and are generally associated with fewer toxicities, but are significantly more expensive. 29 None of the amphotericin B preparations is absorbed orally and they must be given i.v. Amphotericin B is extensively protein bound in serum to lipoproteins via cholesterol, 30 serum albumin and human a1-acid glycoprotein, 31 but liposomal amphotericin largely remains within the liposomes in serum and hence does not appear to be significantly protein bound (Table 3) . 31 The metabolic pathway of amphotericin B and liposomal amphotericin is largely unknown, 28, 32 rendering assessment of the impact of genetic variation somewhat speculative. In the case of amphotericin B deoxycholate, most of the drug is excreted unchanged in urine or faeces with 490% recovered within 7 days, suggesting that little metabolic breakdown occurs. 33 In contrast, o10% of liposomal amphotericin B is excreted unchanged within 7 days, 33 possibly reflecting slow tissue release. 34 No metabolites have been detected from either drug.
There are few data on the interaction of amphotericin B with the CYP system or drug transporters (see Table 4 ). Amphotericin B was associated with reduced levels of hepatic CYP3A4 in patients seropositive for HIV but this may have been because of nonspecific hepatocyte damage. 35 There are currently no data on the interaction of liposomal amphotericin and the CYP enzymes or drug transporters.
Amphotericin B deoxycholate reduces oral bioavailability of ciclosporin, an effect observed clinically. 36 This is mediated via increased expression of the multidrug resistance gene MDR1 in the duodenum causing increased levels of the MDR1 gene product P-gp, 36 but it is not known if liposomal amphotericin has a similar effect. This results in increased efflux of ciclosporin and reduced plasma levels. Interestingly, ciclosporin is itself an inhibitor of P-gp. The MDR1 gene is polymorphic, raising the possibility of variation in the interaction with amphotericin B. These data suggest a possible interaction between amphotericin B deoxycholate and P-gp, and hence with the genetic polymorphisms seen in this transporter.
Overall, however, there is little evidence to support a clinically significant impact of pharmacogenomic variation upon the therapeutic effects of amphotericin B or its lipid formulations.
Triazole antifungals
The azoles have a common mode of action, inhibiting biosynthesis of ergosterol, critical to the integrity of the fungal cell membrane. Specifically, they inhibit 14a-sterol demethylase, an enzyme in the conversion pathway of lanosterol to ergosterol; 37 this demethylase is a member of the CYP450 superfamily found in fungi, designated CYP51A1.
Azoles are both inhibitors and substrates of various human CYP enzymes (Table 4) . This may explain, in part, the plethora of drug interactions between azoles and several other groups of drugs, many of which are clinically relevant to the HSCT recipient. 38 Fluconazole. Fluconazole is a triazole antifungal, with activity against Cryptococcus and many species of Candida, often with reduced activity against Candida glabrata and none against Candida krusei. It is not active against Aspergillus.
Available as oral and i.v. formulations, the oral bioavailability of fluconazole exceeds 90%, 39 and is unaffected by gastric pH, 40 food intake or gastrointestinal disease. 41 It is hydrophilic with minimal protein binding and therefore achieves good tissue penetration into cerebrospinal fluid, saliva, sputum, vagina, skin 41 and brain tissue. 42 Elimination of fluconazole is predominantly renal with no circulating metabolites. 43 Fluconazole inhibits, but is not a substrate of, several CYP enzymes (Table 4) . It inhibits 2C9, 2C19 and to a lesser extent 3A4, 44, 45 but not CYP1A2, 46 2A6 or 2E1. Its ability to inhibit 2C9 and 2C19 causes potential drug interactions particularly relevant to HSCT recipients; for example, the interaction with CY may result in increased formation of toxic metabolites, 47 although others have noted a protective effect of co-administration. 48 Fluconazole is both a substrate 49 and an inhibitor 50 of the UGT isoform, UGT2B7, the enzyme involved in its metabolism to the urinary metabolite fluconazole glucuronide. 43 It also inhibits UGT2B4, hence inhibiting, for example, the glucuronidation of codeine that may potentiate codeine-induced analgesia. 51 The limited involvement of CYP and drug transporters in the uptake and metabolism of fluconazole means that their genetic variation has relatively little impact on fluconazole pharmacokinetics.
Itraconazole. Itraconazole is a triazole antifungal, with activity against Candida species (including some fluconazole- 53 or vitamin C drink 54 ) at low gastric pH. Oral itraconazole solution has increased bioavailability (B30-35%) compared with the capsules, but in contrast to the capsules, is maximally absorbed during fasting. 55 Variations in gastric acidity and the widespread use of proton pump inhibitors in HSCT recipients may decrease absorption of itraconazole. Therefore, use of itraconazole oral solution in these patients, which produces higher serum trough concentrations, 56 is preferred. Itraconazole is also a substrate or inhibitor of several drug transporters (Table 4) .
Itraconazole is extensively protein bound, mainly to albumin, 57 and is predominantly metabolised in the liver, mainly by CYP3A4, for which it is both a substrate and an inhibitor. 58 More than 30 metabolites are formed, 57 including hydroxy-itraconazole, 59 ,60 all of which are inhibitors of CYP3A4 and have a higher affinity for CYP3A4 than itraconazole itself. This may explain the potency of CYP3A4 inhibition seen with itraconazole. 59 Recently, itraconazole was shown to be a substrate for the phase II enzyme UGT1A4, with an affinity similar to that of the imidazole antifungal agents, and it may also be an inhibitor of UGT1A4. 49 Itraconazole interacts with several genetically variable drug transporters and CYP enzymes, thus implicating them in the observed variability of itraconazole levels. Moreover, because CYP3A4 and P-glycoprotein also play a crucial role in the metabolism of many other drugs used in HSCT patients, this effect is likely to be compounded. Enhanced understanding of the pharmacogenomics of itraconazole will optimise itraconazole dosing as well as prediction of toxicities with other drugs.
Voriconazole. Voriconazole is a triazole antifungal, available as i.v. and oral formulations, with excellent oral bioavailability 61 and highly variable nonlinear pharmacokinetics. [62] [63] [64] Excretion of voriconazole occurs predominantly via metabolites in the urine, with limited faecal excretion. 65 Voriconazole has moderate plasma protein binding, but there are limited data on the interaction of voriconazole with the various drug transporters. Voriconazole may interact with CaMdr1p, 66 the yeast homologue of P-gp, and by implication human P-gp.
Genetic polymorphism in CYP2C19 accounts for 49% of the variance in clearance of voriconazole, 67 with recognition of 'poor metaboliser' and 'extensive metaboliser' phenotypes. 17 Levels of voriconazole in poor metabolisers Table 4 Interactions of antifungals with cytochrome P450 enzymes and transporters
Interaction Comments
Amphotericin B No inhibition of CYP3A4 160 or of P-gp in vitro.
Interaction with other transporters unknown. Fluconazole Potent inhibitor of CYP2C9 and CYP2C19, 44, 45 and less so for CYP3A4. 160 No inhibition of P-gp [160] [161] [162] or BCRP. 163 Interaction with ciclosporin via CYP inhibition causes increased ciclosporin levels, especially with oral fluconazole. 164, 165 Itraconazole Substrate for CYP3A4; 57 potent inhibitor of CYP3A4 160 and less so for CYP2C9, CYP2C19. 45 Substrate 166 and inhibitor of P-gp. 160, 161, 167 Conflicting data as to inhibitory effect on OATP. 168, 169 Inhibitor of multidrug resistance protein 3.
170
Inhibitor of BCRP. 163 No inhibition of NTCP or BSEP.
CYP3A4 inhibition will affect metabolism of a variety of drugs to increase their levels (e.g., BU, 171 dexamethasone, 172 midazolam, 173 ciclosporin, 174 tacrolimus, 174 methyl-prednisolone 175 ) or the levels of their metabolites. (e.g., CY 47 ).
Inhibition of P-gp and, therefore P-gp-mediated cellular efflux, may cause increased VCR toxicity, 176 increased ciclosporin, tacrolimus and sirolimus levels, 177 reversal of resistance to vinblastine, DNR and doxorubicin. 178 Voriconazole Substrate for CYP2C19, CYP 3A4, CYP2C9. 73 Inhibitor of CYP2C9, CYP2C19, CYP3A4 and CYP2B6. 179 No inhibition of BCRP. 163 CYP interaction probably accounts for the interaction of voriconazole with many drugs, causing increased levels of tacrolimus, 180 ciclosporin, 181 increased VCR neurotoxicity 182 and reduced clearance of midazolam, 183 particularly the oral formulation of midazolam. Concomitant use of rifabutin, 184 an inducer of CYP and especially of CYP3A4, causes significant reduction in voriconazole levels. Posaconazole
Inhibitor of CYP3A4, but not a substrate of CYP. 185 Inhibitor and substrate of P-gp. 86 Inhibition of CYP3A4 185 results in increased levels of ciclosporin, tacrolimus 186 and midazolam. 185 Genetic polymorphisms of P-gp did not affect posaconazole exposure in healthy individuals. 86 Caspofungin Inhibitor of CYP3A4 58 and NCTP. 96 Not a substrate for CYP1A2, 2A6, 2C9, 2C19, 2D4 or 3A4.
No inhibition of P-gp 96 Substrate and inhibitor of OAT1B1.
96
CYP3A4 inhibition by caspofungin causes a 76% decrease in the metabolism of cytarabine. 187 CYP inducers (e.g., rifampin, nevirapine, efavirenz, carbamazepine, dexamethasome and phenytoin) induce the metabolism of caspofungin. 106 Rifampin may inhibit caspofungin tissue penetration via OATP1. 99 
Micafungin
Slight inhibition of CYP3A4. 160 No inhibition of P-gp. 160 Micafungin inhibition of CYP3A4 increases ciclosporin levels in B20% of patients, 188 but not tacrolimus. 189 Anidulafungin No inhibition of CYP or OATP. 109 Currently, no drug interactions are recorded.
Abbreviations: BCRP ¼ breast cancer resistance protein; BSEP ¼ bile salt export pump; CYP ¼ cytochrome P450; NTCP ¼ Na-taurocholate cotransporting polypeptide; OAT ¼ organic anionic transporters; OATP ¼ organic anionic transporting polypeptide; P-gp ¼ permeability glycoprotein.
can be 4 to 5 times higher than those in extensive metabolisers. 68 A rapid metaboliser 2C19 phenotype has been described, 18 resulting in levels of voriconazole that are significantly lower than either the extensive or poor metaboliser phenotypes. 69 Interestingly, the coexistence of multiple CYP polymorphisms in the same patient do not necessarily have an additive effect on the metabolism of voriconazole. [70] [71] [72] Metabolism of voriconazole results in several metabolites, the major circulating metabolite being the N-oxide of voriconazole, 65 formed predominantly by CYP3A4 and 2C19, with a smaller contribution from 2C9. 73 Production of the methyl hydroxylated metabolite is due solely to CYP3A4.
74 CYP450-mediated metabolism of voriconazole is responsible for B75% of its oxidative metabolism. The remainder is due to flavin-containing mono-oxygenases 75 that also exhibit genetic polymorphism with resultant variations in catalytic activity. 76 Voriconazole is also a low-affinity substrate for UGT1A4 in vitro. 49 An understanding of how genetic polymorphism affects voriconazole metabolism has been pivotal in explaining the pharmacokinetic variability observed in patients. The occurrence of genetic variants in the CYP alleles (Table 4) has a significant impact on the levels of drug achieved in those patients and probably upon the therapeutic efficacy of voriconazole. [77] [78] [79] Posaconazole. Posaconazole is a triazole antifungal, currently only available as an oral suspension. Its bioavailability is significantly improved when taken with food (168% compared with the fasting state), especially if the food is high in fat (290% compared with the fasting state). 80 Doses up to 800 mg/day result in dose-proportional pharmacokinetics, but absorption is saturated at 800 mg/day. 81 Absorption of posaconazole is further improved by splitting the dose (200 mg four times daily compared with 400 mg twice daily) and administering with an acidic beverage or a nutritional supplement. 82, 83 Concomitant dosing with cimetidine 84 or omeprazole 82 both decrease posaconazole serum trough levels, probably because of reduced gastric acidity, an effect likely to be seen with other H 2 receptor agonists or proton pump inhibitors. 85 Data on interactions with transporters demonstrate that posaconazole is both a substrate and an inhibitor of P-gp. 86 The effect of SNPs in P-gp alleles was studied in 28 black and 28 Caucasian healthy volunteers dosed with 400 mg posaconazole twice daily after a meal. Individuals with a SNP resulting in reduced expression of P-gp (n ¼ 13) demonstrated no difference in the area under the curve compared with those with normal levels of P-gp (n ¼ 43). Therefore, the expression of SNPs in P-gp alleles had no effect on posaconazole pharmacokinetics in healthy individuals, 86 but whether this is also true in HSCT recipients, many of whom may have other issues related to absorption and reduced food intake, is not known. There are as yet no data on the interaction of posaconazole with other transporters in the setting of HSCT.
Posaconazole is extensively bound by plasma proteins mainly by serum albumin. 87 In contrast to the other triazoles, posaconazole interacts with fewer CYP enzymes (Table 4) , possibly explaining its narrower drug interaction range.
Posaconazole is excreted largely unchanged; there are no active metabolites 88 and the metabolites seen in urine are glucuronide conjugates, 89 produced by UGT1A4. 90 Genetic variants occur in the alleles for this enzyme, 91 some of which cause reduced catalytic activity. 92 Drug interactions may also occur via the UGT metabolic pathway, including that between posaconazole and phenytoin. 93 Overall, it is likely that the effect of genetic variation on posaconazole pharmacokinetics is relatively small and more related to absorption than metabolism or elimination.
Echinocandins
The echinocandins inhibit b1,3-glucan synthetase, an enzyme involved in fungal cell wall synthesis, leading to increased cell wall permeability and fungal cell lysis. The lack of b1,3-glucan synthetase and cell wall in human cells explains the corresponding lack of toxicity seen with the echinocandins. 94 Caspofungin. Caspofungin is an echinocandin antifungal that is dosed i.v. and is extensively protein bound in plasma, mainly to albumin. Its plasma profile is determined primarily by its rate of distribution from plasma into tissues, rather than by metabolism or excretion. 95 Uptake occurs into hepatocytes via an initial rapid reversible adsorption to the cell surface and a second slow phase of transport across the cell membrane, 95, 96 mediated by organic anion transporter protein 1B1 (OATP1B1). 96 Interactions with other transporters are detailed in Table 4 .
Biotransformation of caspofungin occurs primarily through hydrolysis, rather than by oxidative metabolism. 97 An initial open-ring metabolite is found in plasma, with subsequent peptide degradation resulting in low MW products found in urine. Within 4 weeks, 41% of the dose is excreted in urine and 35% in faeces 98 as metabolites. Caspofungin is the echinocandin with most interaction with the CYP450 system (see Table 4 ).
Rifampin may inhibit the uptake of caspofungin into the tissues via OATP1, with trough levels 14-31% lower after multiple rifampin doses. 99 Genetic polymorphisms of OATP1B1 100 may affect the efficiency of uptake of caspofungin into the liver. However, there are no other known points at which genetic variability affects caspofungin, and hence pharmacogenomic analysis will be of minor importance in optimising use of this antifungal drug.
Micafungin. Micafungin is an echinocandin antifungal that is dosed i.v. It is mainly to bound to albumin and binding is independent of micafungin concentration. 101 Hepatocyte uptake is mediated by both active and passive mechanisms. Na-taurocholate cotransporting polypeptide (NTCP) is most important in uptake, whereas secretion across the canalicular hepatocyte membrane is mediated largely by BSEP (bile sale export pump). MRP3 (multidrug resistance protein 3) mediates transport of micafungin across the sinusoidal hepatocyte membrane. Biliary excretion rather than hepatic uptake is thought to be the rate-limiting step in hepatic elimination of micafungin in humans. 102 Active transport is utilised for both uptake and excretion of micafungin and may be susceptible to genetic variability, as all the transporters involved in the process are known to be polymorphic.
Metabolism of micafungin occurs mainly in the liver, with inactive metabolites excreted in bile and urine. 103 Arylsulfatase is involved in micafungin metabolism, 104 and polymorphisms have been described. 105 In general, however, pharmacogenomic analysis seems unlikely to add much to the clinical use of micafungin.
Anidulafungin. Anidulafungin is an echinocandin antifungal that is dosed i.v. Importantly, anidulafungin has no interactions described with any drug yet studied, 106 including rifampin. 107 Anidulafungin is extensively bound by plasma proteins 108 and undergoes biotransformation, rather than metabolism, undergoing a slow, nonenzymatic degradation to inactive peptides. 97 Neither phase 1 nor phase 2 hepatic metabolism is involved in elimination of anidulafungin, nor is it a substrate, inducer or inhibitor of CYP450. At physiologically relevant concentrations it does not inhibit OATP. 109 Elimination of anidulafungin is via bile in the faeces, with o10% of the drug excreted unchanged in the faeces and o1% in urine. 107, 110 Genetic variation of CYP or phase II enzymes or the hepatic transporters is unlikely to affect anidulafungin pharmacokinetics, given their lack of interaction with anidulafungin, and hence pharmacogenomic analysis will not inform clinical use.
Therapeutic drug monitoring (TDM)
TDM is considered necessary for drugs with (1) unpredictable population pharmacokinetics, (2) a narrow therapeutic index and (3) a defined therapeutic range. 111 Amphotericin B, its lipid formulations and the echinocandins demonstrate predictable pharmacokinetics, and hence TDM is not required. The triazoles are the main agents where TDM is considered helpful in optimising treatment. [111] [112] [113] Although levels of fluconazole can vary significantly between patients, the variability is largely due to renal function, and hence doses are best adjusted according to creatinine clearance. 114 There is increasing evidence to support TDM in routine use of itraconazole, voriconazole and posaconazole.
The methods available for the measurement of drug levels include bioassays, high-performance liquid chromatography and liquid chromatography-mass spectrometry. Bioassays are inherently unreliable in patients receiving more than one antifungal drug, where the assay will usually only measure total antifungal activity and cannot separate out the activity due to each drug. 115 The presence of the microbiologically active metabolite of itraconazole, hydroxy-itraconazole, results in artificially elevated results in itraconazole bioassays. 112 Most laboratories now use either high-performance liquid chromatography or liquid chromatography-mass spectrometry as they are more sensitive, specific and have reduced analytical times. When properly validated, they are capable of measuring the level of an individual drug even in the presence of others. Assessment of a laboratory service for provision of TDM should ensure that the assays are performed regularly and results are communicated in a timely manner to ensure that they are relevant to patient management (see Table 5 ). The therapeutic ranges used vary between laboratories, but data are accumulating to suggest what the optimal ranges should be. Table 5 Assessment of laboratory service for provision of therapeutic drug monitoring (TDM)
Assay is fully validated 190, 191 In salvage therapy for invasive aspergillosis, response rate increased with increasing serum levels and in patients with average levels above 1.25 mg/L response rate was 75%
197 Table 6 summarises therapeutic ranges for itraconazole, voriconazole and posaconazole, and Table 7 lists the suggested indications for TDM. Use of TDM is becoming more widespread and data from reference laboratories indicate that therapeutic levels are not achieved in a significant proportion of routine samples. [116] [117] [118] In compliant patients who have levels persistently out of range, there is an argument to support pharmacogenomic analysis of CYPs, for example, 2C19 in the case of voriconazole. In fact, some clinical laboratories are already providing this service.
The inability to predict serum levels from triazole drug doses, the significant potential for drug interactions, the effects of genetic variation on pharmacokinetics and the correlation between improved outcomes with higher serum levels all add to the weight of evidence supporting TDM in HSCT recipients.
Conclusions and future perspectives
Antifungal efficacy in invasive fungal infection is dependent on systemic drug exposure; therefore, maximising the absorption and distribution of antifungals to relevant tissues is essential for favourable treatment outcomes. The potential for genetically induced variation in metabolism of antifungal drugs, and the knock-on effect on drug interactions, remains largely theoretical, pending systematic laboratory evaluation. Such experience will clarify the relative importance of specific polymorphisms. However, there is already ample evidence of clinically relevant pharmacogenetic influence in the case of the azoles, particularly voriconazole. In contrast, its role in the use of amphotericin B and the echinocandins may be less important, because of their distinct metabolic and elimination pathways.
Genetic variation affects susceptibility to fungal infection, 119 metabolism and drug interactions of antifungals and, it is now emerging, the development of resistance to the azoles in Aspergillus fumigatus. 120, 121 Unsurprisingly, mutations of fungal CYP51, a prime target of the triazoles, seem to mediate the predominant resistance pathways. 122 Large-scale screening for SNPs in relevant human genes, using next-generation sequencing techniques, 123 is now feasible. As scientists unravel the journey of antifungal drugs through the body and the many enzymes and transporters encountered en route, we will benefit from a better understanding of how genetic variation affects pharmacokinetics. An individual will have a unique profile of susceptibility to invasive fungal infection, 119 metabolic handling of and response to antifungal therapy. Meaningful analysis of this genomic profile is a tantalising prospect on the horizon, if not quite within our grasp. The transition from horizon to clinic will depend upon a better understanding of the costs and benefits, particularly in the current economic climate.
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